ID: ALA13130

Max Phase: Preclinical

Molecular Formula: C10H15N4O4P

Molecular Weight: 286.23

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=P(O)(O)CCCCCn1cnc2c(O)ncnc21

Standard InChI:  InChI=1S/C10H15N4O4P/c15-10-8-9(11-6-12-10)14(7-13-8)4-2-1-3-5-19(16,17)18/h6-7H,1-5H2,(H,11,12,15)(H2,16,17,18)

Standard InChI Key:  HKVZDTLGAPBOBY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 286.23

Molecular Weight (Monoisotopic): 286.0831

AlogP: 0.88

#Rotatable Bonds: 6

Polar Surface Area: 121.36

Molecular Species: ACID

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 1.83

CX Basic pKa: 0.52

CX LogP: -0.39

CX LogD: -2.56

Aromatic Rings: 2

Heavy Atoms: 19

QED Weighted: 0.53

Np Likeness Score: -0.62

References

1. Guida WC, Elliott RD, Thomas HJ, Secrist JA, Babu YS, Bugg CE, Erion MD, Ealick SE, Montgomery JA..  (1994)  Structure-based design of inhibitors of purine nucleoside phosphorylase. 4. A study of phosphate mimics.,  37  (8): [PMID:8164252] [10.1021/jm00034a008]

2. Niwas S, Chand P, Pathak VP, Montgomery JA..  (1994)  Structure-based design of inhibitors of purine nucleoside phosphorylase. 5. 9-Deazahypoxanthines.,  37  (15): [PMID:8057293] [10.1021/jm00041a027]

3. Česnek M, Hocková D, Holý A, Dračínský M, Baszczyňski O, Jersey Jd, Keough DT, Guddat LW..  (2012)  Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.,  20  (2): [PMID:22178188] [10.1016/j.bmc.2011.11.034]

Source

Source(1):

• Scientific Literature